Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin effects on insulin sensitivity in T2D
NCT00351546Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started Feb 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00351546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351546.